Deals Shaping The Medical Industry, July 2018
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment (in vitro diagnostics, medical devices and pharmaceuticals) and then categorized by type (acquisition, alliance or financing). This month’s column covers deals announced in June 2018.
You may also be interested in...
Johnson & Johnson’s leadership remains optimistic about the future of its medical device divisions despite reporting a 2.6% revenue decline in the first six months of 2019 compared to the same period of 2018.
During Q1, biopharmas brought in an aggregate $13.8bn in financing. M&A value reached $6.9bn, the majority from Gilead Sciences $4.9bn purchase of immuno-oncology firm Forty Seven. Alliances fetched $35bn in potential deal value, dominated by many Big Pharma tie-ups led by a $4bn discovery and development collaboration between AstraZeneca and Silence Therapeutics for siRNA therapeutics.
AstraZeneca and Silence Therapeutics entered a March alliance worth up to $4.08bn for the discovery and development of siRNA drugs for cardiovascular, renal, metabolic and respiratory diseases, while the top April deal was a $3.9bn tie up between Fate Therapeutics and Janssen for iPSC-derived cell-based cancer immunotherapies.